NASDAQ:IMCR
Immunocore Holdings plc
Immunocore Holdings plc's revenue grew 29.0% in fiscal 2025 to $400.0M while operating margin rose to −11.3%, its highest in 5 years. Free cash flow was −$15.1M, −3.8% of revenue, and the diluted share count rose 0.7%.Summary generated from Immunocore Holdings plc's SEC filings. Latest annual report filed Feb 25, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$400.0M
Revenue growth+29.0%
Revenue, 5-yr CAGRn/a
Gross margin98.7%
Operating margin−11.3%
Net margin−8.9%
ROICn/a
Return on equity−9.6%
Debt / equityn/a
Free cash flow−$15.1M
FCF margin−3.8%
Share count change+0.7%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 36 | 174 | 249 | 310 | 400 |
| Operating income | −175 | −52 | −60 | −70 | −45 |
| Net income | −180 | −53 | −55 | −51 | −36 |
| Free cash flow | −144 | −51 | −2 | 21 | −15 |
Recent filings
- 8-KRegulation FD disclosure
Sep 14, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 4Insider transaction report
May 28, 2026 - 4Insider transaction report
May 28, 2026 - 8-KResults of a shareholder vote
May 27, 2026 - 8-KResults of operations and financial condition
May 6, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 6, 2026